Share Price and Basic Stock Data
Last Updated: November 20, 2025, 9:46 pm
| PEG Ratio | -1.98 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Camex Ltd operates within the specialty chemicals sector, focusing on niche markets that cater to specific customer needs. As of the latest report, the company’s stock price stood at ₹35.5, with a market capitalization of ₹36.2 Cr. Over the recent quarters, revenue trends exhibited volatility, with quarterly sales peaking at ₹40.36 Cr in March 2023 and showing a gradual decline to ₹34.37 Cr by December 2023. The annual sales figures reflect a similar pattern, where sales reported for FY 2023 were ₹132 Cr, slightly lower than FY 2022’s ₹162 Cr. Despite these fluctuations, the trailing twelve months (TTM) revenue stood at ₹137 Cr, indicating a modest recovery compared to the previous fiscal year. The company’s operational performance was impacted by rising expenses, which saw an annual total of ₹131 Cr in FY 2023, emphasizing the need for improved cost management strategies. This revenue trend highlights the challenges Camex Ltd faces in achieving consistent growth amidst a competitive chemical industry landscape.
Profitability and Efficiency Metrics
The profitability metrics of Camex Ltd reveal significant challenges, primarily reflected in its operating profit margin (OPM), which stood at a mere 5.54%. The company reported a net profit of ₹0, indicating that operational efficiency remains a critical area for improvement. Over the recent quarters, the operating profit fluctuated, reaching a high of ₹2.10 Cr in March 2024, but faced downturns, including a negative operating profit of ₹0.29 Cr in June 2023. The interest coverage ratio (ICR) reported at 2.34x suggests that the company can comfortably cover its interest expenses, although it indicates a relatively low buffer. The return on equity (ROE) at 4.63% and return on capital employed (ROCE) at 9.07% are below sector averages, indicating that capital efficiency could be enhanced. These figures underscore a pressing need for Camex Ltd to implement robust cost control measures and enhance its revenue-generating capabilities to improve its overall profitability and operational efficiency.
Balance Sheet Strength and Financial Ratios
Camex Ltd’s balance sheet reflects a cautious financial structure, with no reported borrowings, which positions the company in a potentially advantageous situation concerning interest expenses. The price-to-book value (P/BV) ratio is at 0.71x, indicating that the stock is trading at a discount to its book value, which may suggest undervaluation in the market. The company’s cash conversion cycle (CCC) stood at 51 days, reflecting a reasonable efficiency in converting investments into cash flows. However, the absence of reserves indicates limited financial cushioning for unforeseen expenses or downturns. The current ratio at 3.74x suggests a strong liquidity position, enabling the company to meet short-term obligations comfortably. Yet, the overall financial ratios indicate a need for strategic improvements in both asset utilization and profit generation to strengthen the balance sheet further and enhance shareholder value.
Shareholding Pattern and Investor Confidence
The shareholding structure of Camex Ltd shows a predominance of public investors, who held 55.24% of the shares as of the latest report, while promoters owned 44.76%. Notably, there has been a decline in promoter holding from 58.28% in December 2022 to the current levels, which may raise concerns regarding insider confidence in the company’s future prospects. The presence of foreign institutional investors (FIIs) is not applicable, and domestic institutional investors (DIIs) hold a negligible 0.01%. This lack of institutional backing could indicate a lower level of confidence among larger investors regarding the company’s growth trajectory. Furthermore, the number of shareholders has fluctuated, reflecting changing investor sentiment, from 3,949 shareholders recently to a high of 4,207 in June 2024. This volatility in shareholding dynamics signals a potential need for enhanced investor communication and engagement strategies to bolster confidence in the company’s long-term vision.
Outlook, Risks, and Final Insight
Camex Ltd faces several strengths and risks that will shape its strategic outlook. The absence of debt presents a significant strength, allowing for more operational flexibility and lower financial risk. Additionally, the company’s ability to generate a TTM revenue of ₹137 Cr shows resilience in a challenging market. However, risks are evident, particularly in profitability metrics and declining promoter shareholding, which may affect market perception. The company must address its operational inefficiencies and explore avenues for revenue growth to enhance profitability. Looking ahead, if Camex Ltd can stabilize its operational performance and restore investor confidence through strategic initiatives, it may position itself for long-term growth. Conversely, persistent challenges in managing costs and maintaining market share could hinder its recovery and growth trajectory, necessitating careful monitoring and responsive strategies in an evolving market landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Camex Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| HP Adhesives Ltd | 430 Cr. | 47.0 | 86.7/42.6 | 26.7 | 20.5 | 0.85 % | 13.6 % | 9.82 % | 2.00 |
| Haryana Leather Chemicals Ltd | 35.8 Cr. | 73.0 | 103/56.0 | 17.2 | 89.6 | 1.37 % | 8.02 % | 5.45 % | 10.0 |
| Hardcastle & Waud Mfg Co Ltd | 44.9 Cr. | 661 | 988/600 | 20.7 | 697 | 0.00 % | 6.31 % | 2.91 % | 10.0 |
| Grauer & Weil (India) Ltd | 3,717 Cr. | 82.0 | 111/78.0 | 24.6 | 22.0 | 0.61 % | 23.3 % | 17.6 % | 1.00 |
| DMCC Speciality Chemicals Ltd | 663 Cr. | 266 | 453/241 | 23.8 | 93.8 | 0.94 % | 14.1 % | 9.97 % | 10.0 |
| Industry Average | 12,962.80 Cr | 744.41 | 64.06 | 182.93 | 0.42% | 12.99% | 25.41% | 6.41 |
Quarterly Result
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 39.72 | 30.61 | 30.58 | 30.33 | 40.36 | 34.13 | 35.22 | 34.37 | 37.59 | 33.84 | 34.39 | 28.21 | 37.21 |
| Expenses | 40.21 | 29.97 | 31.03 | 30.76 | 39.86 | 34.42 | 34.11 | 33.15 | 35.49 | 32.95 | 33.01 | 28.58 | 35.15 |
| Operating Profit | -0.49 | 0.64 | -0.45 | -0.43 | 0.50 | -0.29 | 1.11 | 1.22 | 2.10 | 0.89 | 1.38 | -0.37 | 2.06 |
| OPM % | -1.23% | 2.09% | -1.47% | -1.42% | 1.24% | -0.85% | 3.15% | 3.55% | 5.59% | 2.63% | 4.01% | -1.31% | 5.54% |
| Other Income | 3.68 | 0.39 | 0.58 | 0.35 | 0.62 | 0.37 | 0.44 | 0.52 | 0.25 | 0.33 | 1.15 | 0.29 | -1.01 |
| Interest | 0.46 | 0.26 | 0.18 | 0.34 | 0.23 | 0.25 | 0.21 | 0.12 | 0.18 | 0.33 | 0.45 | 0.31 | 0.24 |
| Depreciation | 0.19 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.07 | 0.07 | 0.09 | 0.35 |
| Profit before tax | 2.54 | 0.69 | -0.13 | -0.50 | 0.81 | -0.25 | 1.26 | 1.54 | 2.09 | 0.82 | 2.01 | -0.48 | 0.46 |
| Tax % | 16.93% | 26.09% | -46.15% | -14.00% | 23.46% | 0.00% | 21.43% | 24.68% | 25.84% | 24.39% | 27.36% | -35.42% | 69.57% |
| Net Profit | 2.10 | 0.51 | -0.08 | -0.44 | 0.62 | -0.24 | 0.99 | 1.16 | 1.55 | 0.61 | 1.46 | -0.32 | 0.15 |
| EPS in Rs | 2.06 | 0.50 | -0.08 | -0.43 | 0.61 | -0.24 | 0.97 | 1.14 | 1.52 | 0.60 | 1.43 | -0.31 | 0.15 |
Last Updated: May 31, 2025, 6:37 am
Below is a detailed analysis of the quarterly data for Camex Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 37.21 Cr.. The value appears strong and on an upward trend. It has increased from 28.21 Cr. (Dec 2024) to 37.21 Cr., marking an increase of 9.00 Cr..
- For Expenses, as of Mar 2025, the value is 35.15 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 28.58 Cr. (Dec 2024) to 35.15 Cr., marking an increase of 6.57 Cr..
- For Operating Profit, as of Mar 2025, the value is 2.06 Cr.. The value appears strong and on an upward trend. It has increased from -0.37 Cr. (Dec 2024) to 2.06 Cr., marking an increase of 2.43 Cr..
- For OPM %, as of Mar 2025, the value is 5.54%. The value appears strong and on an upward trend. It has increased from -1.31% (Dec 2024) to 5.54%, marking an increase of 6.85%.
- For Other Income, as of Mar 2025, the value is -1.01 Cr.. The value appears to be declining and may need further review. It has decreased from 0.29 Cr. (Dec 2024) to -1.01 Cr., marking a decrease of 1.30 Cr..
- For Interest, as of Mar 2025, the value is 0.24 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.31 Cr. (Dec 2024) to 0.24 Cr., marking a decrease of 0.07 Cr..
- For Depreciation, as of Mar 2025, the value is 0.35 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.09 Cr. (Dec 2024) to 0.35 Cr., marking an increase of 0.26 Cr..
- For Profit before tax, as of Mar 2025, the value is 0.46 Cr.. The value appears strong and on an upward trend. It has increased from -0.48 Cr. (Dec 2024) to 0.46 Cr., marking an increase of 0.94 Cr..
- For Tax %, as of Mar 2025, the value is 69.57%. The value appears to be increasing, which may not be favorable. It has increased from -35.42% (Dec 2024) to 69.57%, marking an increase of 104.99%.
- For Net Profit, as of Mar 2025, the value is 0.15 Cr.. The value appears strong and on an upward trend. It has increased from -0.32 Cr. (Dec 2024) to 0.15 Cr., marking an increase of 0.47 Cr..
- For EPS in Rs, as of Mar 2025, the value is 0.15. The value appears strong and on an upward trend. It has increased from -0.31 (Dec 2024) to 0.15, marking an increase of 0.46.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 3:43 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 221 | 147 | 102 | 103 | 121 | 140 | 122 | 143 | 162 | 132 | 142 | 134 | 137 |
| Expenses | 215 | 141 | 98 | 99 | 116 | 134 | 119 | 140 | 159 | 131 | 137 | 130 | 134 |
| Operating Profit | 7 | 6 | 4 | 4 | 6 | 7 | 3 | 3 | 2 | 1 | 5 | 4 | 3 |
| OPM % | 3% | 4% | 4% | 4% | 5% | 5% | 3% | 2% | 1% | 0% | 3% | 3% | 2% |
| Other Income | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 5 | 2 | 1 | 1 | -1 |
| Interest | 4 | 3 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 |
| Profit before tax | 3 | 2 | 1 | 2 | 3 | 4 | 1 | 2 | 5 | 1 | 5 | 3 | 1 |
| Tax % | 33% | 33% | 33% | 34% | 34% | 23% | 29% | 18% | 17% | 29% | 25% | 32% | |
| Net Profit | 2 | 1 | 1 | 2 | 2 | 3 | 1 | 2 | 4 | 1 | 3 | 2 | 0 |
| EPS in Rs | 1.88 | 1.39 | 0.90 | 1.60 | 2.09 | 3.08 | 0.94 | 1.96 | 4.13 | 0.60 | 3.39 | 1.85 | 0.45 |
| Dividend Payout % | 27% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -50.00% | 0.00% | 100.00% | 0.00% | 50.00% | -66.67% | 100.00% | 100.00% | -75.00% | 200.00% | -33.33% |
| Change in YoY Net Profit Growth (%) | 0.00% | 50.00% | 100.00% | -100.00% | 50.00% | -116.67% | 166.67% | 0.00% | -175.00% | 275.00% | -233.33% |
Camex Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | 2% |
| 3 Years: | -6% |
| TTM: | -5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 15% |
| 3 Years: | 0% |
| TTM: | -48% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 21% |
| 3 Years: | 14% |
| 1 Year: | -29% |
| Return on Equity | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 5% |
| 3 Years: | 5% |
| Last Year: | 5% |
Last Updated: September 5, 2025, 2:46 pm
No data available for the Balance Sheet data table.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 73 | 68 | 87 | 98 | 103 | 82 | 77 | 98 | 70 | 82 | 61 | 60 |
| Inventory Days | 18 | 27 | 28 | 44 | 42 | 38 | 31 | 45 | 16 | 31 | 23 | 40 |
| Days Payable | 13 | 25 | 29 | 28 | 21 | 36 | 47 | 71 | 32 | 45 | 32 | 50 |
| Cash Conversion Cycle | 78 | 71 | 86 | 115 | 123 | 83 | 61 | 72 | 54 | 67 | 52 | 51 |
| Working Capital Days | 31 | 40 | 62 | 66 | 69 | 60 | 63 | 79 | 75 | 101 | 84 | 88 |
| ROCE % | 11% | 10% | 8% | 9% | 11% | 12% | 6% | 7% | 7% | 5% | 12% | 9% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 22 | Mar 21 | Mar 20 | Mar 19 | Mar 18 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 3.19 | 1.37 | 1.21 | 3.61 | 2.23 |
| Diluted EPS (Rs.) | 3.19 | 1.37 | 1.21 | 3.61 | 2.23 |
| Cash EPS (Rs.) | 3.97 | 2.27 | 2.58 | 4.52 | 3.02 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 38.95 | 33.24 | 31.93 | 30.55 | 26.81 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 38.95 | 33.24 | 31.93 | 30.55 | 26.81 |
| Revenue From Operations / Share (Rs.) | 175.58 | 147.10 | 129.23 | 144.20 | 126.22 |
| PBDIT / Share (Rs.) | 2.98 | 3.36 | 3.80 | 7.25 | 6.17 |
| PBIT / Share (Rs.) | 2.12 | 2.43 | 2.44 | 6.34 | 5.39 |
| PBT / Share (Rs.) | 3.99 | 1.75 | 1.61 | 4.54 | 3.29 |
| Net Profit / Share (Rs.) | 3.12 | 1.33 | 1.23 | 3.61 | 2.23 |
| NP After MI And SOA / Share (Rs.) | 3.08 | 1.33 | 1.23 | 3.61 | 2.23 |
| PBDIT Margin (%) | 1.69 | 2.28 | 2.93 | 5.02 | 4.89 |
| PBIT Margin (%) | 1.20 | 1.65 | 1.89 | 4.39 | 4.26 |
| PBT Margin (%) | 2.27 | 1.19 | 1.24 | 3.15 | 2.60 |
| Net Profit Margin (%) | 1.77 | 0.90 | 0.95 | 2.50 | 1.76 |
| NP After MI And SOA Margin (%) | 1.75 | 0.90 | 0.95 | 2.50 | 1.76 |
| Return on Networth / Equity (%) | 8.46 | 4.00 | 3.84 | 11.82 | 8.32 |
| Return on Capital Employeed (%) | 4.46 | 5.95 | 7.41 | 18.00 | 14.66 |
| Return On Assets (%) | 4.83 | 1.68 | 2.26 | 5.96 | 3.28 |
| Long Term Debt / Equity (X) | 0.22 | 0.20 | 0.00 | 0.11 | 0.32 |
| Total Debt / Equity (X) | 0.23 | 0.51 | 0.07 | 0.43 | 1.09 |
| Asset Turnover Ratio (%) | 2.29 | 2.16 | 2.19 | 2.22 | 1.95 |
| Current Ratio (X) | 3.74 | 1.85 | 2.10 | 1.99 | 1.86 |
| Quick Ratio (X) | 2.91 | 1.45 | 1.69 | 1.51 | 1.48 |
| Inventory Turnover Ratio (X) | 3.32 | 3.77 | 3.79 | 2.85 | 2.69 |
| Interest Coverage Ratio (X) | 2.34 | 4.98 | 4.56 | 4.04 | 2.95 |
| Interest Coverage Ratio (Post Tax) (X) | 0.98 | 2.97 | 2.48 | 3.01 | 2.07 |
| Enterprise Value (Cr.) | 35.37 | 36.38 | 11.99 | 44.10 | 62.50 |
| EV / Net Operating Revenue (X) | 0.19 | 0.24 | 0.09 | 0.29 | 0.48 |
| EV / EBITDA (X) | 11.63 | 10.59 | 3.09 | 5.96 | 9.91 |
| MarketCap / Net Operating Revenue (X) | 0.14 | 0.13 | 0.07 | 0.22 | 0.27 |
| Price / BV (X) | 0.71 | 0.59 | 0.31 | 1.04 | 1.31 |
| Price / Net Operating Revenue (X) | 0.14 | 0.13 | 0.07 | 0.22 | 0.27 |
| EarningsYield | 0.11 | 0.06 | 0.12 | 0.11 | 0.06 |
After reviewing the key financial ratios for Camex Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 22, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 21) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 22, the value is 3.19. This value is below the healthy minimum of 5. It has increased from 1.37 (Mar 21) to 3.19, marking an increase of 1.82.
- For Diluted EPS (Rs.), as of Mar 22, the value is 3.19. This value is below the healthy minimum of 5. It has increased from 1.37 (Mar 21) to 3.19, marking an increase of 1.82.
- For Cash EPS (Rs.), as of Mar 22, the value is 3.97. This value is within the healthy range. It has increased from 2.27 (Mar 21) to 3.97, marking an increase of 1.70.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 22, the value is 38.95. It has increased from 33.24 (Mar 21) to 38.95, marking an increase of 5.71.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 22, the value is 38.95. It has increased from 33.24 (Mar 21) to 38.95, marking an increase of 5.71.
- For Revenue From Operations / Share (Rs.), as of Mar 22, the value is 175.58. It has increased from 147.10 (Mar 21) to 175.58, marking an increase of 28.48.
- For PBDIT / Share (Rs.), as of Mar 22, the value is 2.98. This value is within the healthy range. It has decreased from 3.36 (Mar 21) to 2.98, marking a decrease of 0.38.
- For PBIT / Share (Rs.), as of Mar 22, the value is 2.12. This value is within the healthy range. It has decreased from 2.43 (Mar 21) to 2.12, marking a decrease of 0.31.
- For PBT / Share (Rs.), as of Mar 22, the value is 3.99. This value is within the healthy range. It has increased from 1.75 (Mar 21) to 3.99, marking an increase of 2.24.
- For Net Profit / Share (Rs.), as of Mar 22, the value is 3.12. This value is within the healthy range. It has increased from 1.33 (Mar 21) to 3.12, marking an increase of 1.79.
- For NP After MI And SOA / Share (Rs.), as of Mar 22, the value is 3.08. This value is within the healthy range. It has increased from 1.33 (Mar 21) to 3.08, marking an increase of 1.75.
- For PBDIT Margin (%), as of Mar 22, the value is 1.69. This value is below the healthy minimum of 10. It has decreased from 2.28 (Mar 21) to 1.69, marking a decrease of 0.59.
- For PBIT Margin (%), as of Mar 22, the value is 1.20. This value is below the healthy minimum of 10. It has decreased from 1.65 (Mar 21) to 1.20, marking a decrease of 0.45.
- For PBT Margin (%), as of Mar 22, the value is 2.27. This value is below the healthy minimum of 10. It has increased from 1.19 (Mar 21) to 2.27, marking an increase of 1.08.
- For Net Profit Margin (%), as of Mar 22, the value is 1.77. This value is below the healthy minimum of 5. It has increased from 0.90 (Mar 21) to 1.77, marking an increase of 0.87.
- For NP After MI And SOA Margin (%), as of Mar 22, the value is 1.75. This value is below the healthy minimum of 8. It has increased from 0.90 (Mar 21) to 1.75, marking an increase of 0.85.
- For Return on Networth / Equity (%), as of Mar 22, the value is 8.46. This value is below the healthy minimum of 15. It has increased from 4.00 (Mar 21) to 8.46, marking an increase of 4.46.
- For Return on Capital Employeed (%), as of Mar 22, the value is 4.46. This value is below the healthy minimum of 10. It has decreased from 5.95 (Mar 21) to 4.46, marking a decrease of 1.49.
- For Return On Assets (%), as of Mar 22, the value is 4.83. This value is below the healthy minimum of 5. It has increased from 1.68 (Mar 21) to 4.83, marking an increase of 3.15.
- For Long Term Debt / Equity (X), as of Mar 22, the value is 0.22. This value is within the healthy range. It has increased from 0.20 (Mar 21) to 0.22, marking an increase of 0.02.
- For Total Debt / Equity (X), as of Mar 22, the value is 0.23. This value is within the healthy range. It has decreased from 0.51 (Mar 21) to 0.23, marking a decrease of 0.28.
- For Asset Turnover Ratio (%), as of Mar 22, the value is 2.29. It has increased from 2.16 (Mar 21) to 2.29, marking an increase of 0.13.
- For Current Ratio (X), as of Mar 22, the value is 3.74. This value exceeds the healthy maximum of 3. It has increased from 1.85 (Mar 21) to 3.74, marking an increase of 1.89.
- For Quick Ratio (X), as of Mar 22, the value is 2.91. This value exceeds the healthy maximum of 2. It has increased from 1.45 (Mar 21) to 2.91, marking an increase of 1.46.
- For Inventory Turnover Ratio (X), as of Mar 22, the value is 3.32. This value is below the healthy minimum of 4. It has decreased from 3.77 (Mar 21) to 3.32, marking a decrease of 0.45.
- For Interest Coverage Ratio (X), as of Mar 22, the value is 2.34. This value is below the healthy minimum of 3. It has decreased from 4.98 (Mar 21) to 2.34, marking a decrease of 2.64.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 22, the value is 0.98. This value is below the healthy minimum of 3. It has decreased from 2.97 (Mar 21) to 0.98, marking a decrease of 1.99.
- For Enterprise Value (Cr.), as of Mar 22, the value is 35.37. It has decreased from 36.38 (Mar 21) to 35.37, marking a decrease of 1.01.
- For EV / Net Operating Revenue (X), as of Mar 22, the value is 0.19. This value is below the healthy minimum of 1. It has decreased from 0.24 (Mar 21) to 0.19, marking a decrease of 0.05.
- For EV / EBITDA (X), as of Mar 22, the value is 11.63. This value is within the healthy range. It has increased from 10.59 (Mar 21) to 11.63, marking an increase of 1.04.
- For MarketCap / Net Operating Revenue (X), as of Mar 22, the value is 0.14. This value is below the healthy minimum of 1. It has increased from 0.13 (Mar 21) to 0.14, marking an increase of 0.01.
- For Price / BV (X), as of Mar 22, the value is 0.71. This value is below the healthy minimum of 1. It has increased from 0.59 (Mar 21) to 0.71, marking an increase of 0.12.
- For Price / Net Operating Revenue (X), as of Mar 22, the value is 0.14. This value is below the healthy minimum of 1. It has increased from 0.13 (Mar 21) to 0.14, marking an increase of 0.01.
- For EarningsYield, as of Mar 22, the value is 0.11. This value is below the healthy minimum of 5. It has increased from 0.06 (Mar 21) to 0.11, marking an increase of 0.05.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Camex Ltd:
- Net Profit Margin: 1.77%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 4.46% (Industry Average ROCE: 12.99%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 8.46% (Industry Average ROE: 25.41%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0.98
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.91
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 71 (Industry average Stock P/E: 64.06)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.23
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 1.77%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Speciality - Others | Camex House, 2nd Floor, Ahmedabad Gujarat 380009 | cs@camexltd.com http://www.camexltd.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Chandraprakash Chopra | Managing Director |
| Mr. Rajesh Nahata | Executive Director |
| Mr. Rahul Chopra | Non Executive Director |
| Mrs. Tara Jain | Ind. Non-Executive Director |
| Mr. Uttam Bhandari | Ind. Non-Executive Director |
| Mr. Jagrit Sanklecha | Additional Director |